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Delineate Signaling Crosstalk: Type I
and II Interferons Enhance NFκB via
Distinct Mechanisms
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Quen J. Cheng 1, Gourisankar Ghosh 3 and Alexander Hoffmann 1,2*
1 Signaling Systems Laboratory, Institute for Quantitative and Computational Biosciences, Department of Microbiology,
Immunology, and Molecular Genetics, and Molecular Biology Institute, University of California Los Angeles, Los Angeles, CA,
United States, 2 Signaling Systems Laboratory, San Diego Center for Systems Biology, La Jolla, CA, United States,
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Nuclear factor kappa B (NFκB) is a transcription factor that controls inflammation
and cell survival. In clinical histology, elevated NFκB activity is a hallmark of poor
prognosis in inflammatory disease and cancer, and may be the result of a combination
of diverse micro-environmental constituents. While previous quantitative studies of NFκB
focused on its signaling dynamics in single cells, we address here how multiple stimuli
may combine to control tissue level NFκB activity. We present a novel, simplified
model of NFκB (SiMoN) that functions as an NFκB activity calculator. We demonstrate
its utility by exploring how type I and type II interferons modulate NFκB activity in
macrophages. Whereas, type I IFNs potentiate NFκB activity by inhibiting translation
of IκBα and by elevating viral RNA sensor (RIG-I) expression, type II IFN amplifies
NFκB activity by increasing the degradation of free IκB through transcriptional induction
of proteasomal cap components (PA28). Both cross-regulatory mechanisms amplify
NFκB activation in response to weaker (viral) inducers, while responses to stronger
(bacterial or cytokine) inducers remain largely unaffected. Our work demonstrates how
the NFκB calculator can reveal distinct mechanisms of crosstalk on NFκB activity in
interferon-containing microenvironments.
Keywords: mathematical model, signaling crosstalk, interferon, NFκB, systems biology, translational inhibition,
immunoproteasome, anti-viral response
INTRODUCTION
NFκB is the primary transcriptional regulator of inflammation (1), controlling the expression of
inflammatory cytokines and chemokines that activate and coordinate both local and systemic
immune responses, as well as tissue remodeling factors that facilitate immune cell invasion and
tissue repair (2). Furthermore, NFκB controls cell survival genes and its activity is associated with
chemoresistance in cancer cells (3). As a result, high NFκB activity in chronic disease is often
associated with poor prognosis (4). Indeed, clinical histological screening to inform treatment
strategies often involves assessment of NFκB expression or activity (5, 6).
The molecular mechanisms by which the primary NFκB protein RelA is activated in response to
inflammatory cytokines or pathogen exposure have been elucidated. Inflammatory stimuli induce
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phosphorylation by the IκB kinase (IKK) complex of IκBs,
triggering their ubiquitin-dependent proteasomal degradation,
and thus freeing NFκB to translocate to the nucleus to bind to
DNA κB elements and induce transcription of target genes. NFκB
target genes include several IκBs, which upon induction provide
negative feedback on the system thus regulating the dynamics of
NFκB activity (7–9).
Mathematical kinetic models of the IκB-NFκB signaling
module have contributed to our understanding of the complex
and often oscillatory dynamics of NFκB activity observed in
single cells stimulated with a defined inflammatory agonist
(10). However, due to cellular heterogeneity such oscillatory
responses are rarely observed at the cell population level (11,
12). In primary or tissues cells such dynamic heterogeneity is
likely to be even greater given their differential steady states
(13). Indeed, in various clinical settings, overall NFκB activity
in cell populations (average nuclear localization across many
cells) examined in tissues has prognostic value. While recent
studies have distributed the state of single-cell simulations to
estimate cell population behavior (13, 14) such approaches are
computationally challenging due to the need to numerically solve
a large system of equations for each cell in the simulation. This
may preclude comprehensive parameter scanning, preventing
full characterization of possible responses. Only small models can
be analytically solved to obtain concentrations without the need
for relatively slow computational numerical solvers. In addition,
due to the number of molecular species in larger models that
cannot be experimentally measured, the iterative interpretation
of experimental results with computational simulation can be
challenging. For a given experimental observation, multiple
reaction rates can often be perturbed to explain the result leading
to challenges in targeting the next experiment. This calls for
a simplified modeling framework that coarse-grains the known
regulatory mechanisms when the data of interest do not demand
detailed models. Simplified models of NFκB have previously
been constructed and shown to be useful in elucidating the
regulatory principles underlying its oscillatory control of single
cells (15–18). However, no models have been reported that
focus on the regulatory principles governing the quantitative
average NFκB activity of many cells i.e., models that recapitulate
the tissue scale NFκB activity. Though models representing
the aggregate behavior of multiple cells or entire organs, i.e.,
tissue-scale models, are further abstractions of the regulatory
mechanisms than models that recapitulate the intra-cellular
regulatory dynamic, they have proven useful to investigate
the dose-response and time-evolution of diverse biological
phenomena, such as hormone control and the interplay
between organ function, drug metabolism, and the responses to
drugs (19–21).
One diverse cytokine family that defines tissue
microenvironments are the interferons (22); the most
prominent family members, IFNβ and IFNγ, exemplify
type I and type II interferons, respectively. Interferons
are typically coordinately activated with NFκB in sites of
infection and play roles in inflammatory disease even if their
primary physiological function is anti-viral gene expression.
Indeed, both clinical and experimental studies point to
crosstalk by interferons on NFκB-driven inflammatory
signaling (23–27). For example, inflammatory symptoms
and cytokine secretion during an infection with streptococcus
pneumoniae are exacerbated by infection with influenza.
Similar clinical symptoms during leishmaniasis are observed
when the parasites harbor the Leishmania RNA Virus (LRV)
(28, 29).
Laboratory studies have proposed two broad classes of
cross-regulatory mechanisms: one mediated by chromatin,
altering how induced NFκB controls gene expression, and
the other mediated by the signaling networks, affecting
the level of NFκB activity. In line with the former, IFN-
mediated RNA pol II recruitment or IFN-mediated chromatin
remodeling of NFκB-inducible genes have been identified as
mechanisms potentiating inflammatory gene expression (30–
34). In regards to the latter, IFNs have been reported to
affect NFκB activity by altering signal transduction between
TLRs and NFκB via expression of receptors, co-receptors
and adapter proteins (35–41), or by altering translation
control through phosphorylating eukaryotic initiation factors
(eIF)2α and eIF4E, which may also diminish translation of
IκBα (40, 42–45). However, these mechanisms must allow
for a level of stimulus-specificity, as TLR4-mediated NFκB
activation was, for example, found to be unaffected by
IFNγ (34).
Here we construct a simple model of NFκB control, termed
SiMoN, to capture the activity of populations of cells and employ
it in an iterative and quantitative systems biology study to
investigate how signaling crosstalk by micro-environmental type
I and II IFNs influences NFκB signaling. We identify distinct,
IFN type-specific mechanisms that amplify NFκB activation in
a stimulus-specific manner.
RESULTS
A Simplified Model of NFκB Activity for
Studying Cross-Regulation
Previously published mathematical models accurately
recapitulate transient NFκB activities and oscillations caused
by stimuli such as TNF or LPS (11, 12, 46–48) in fibroblasts
and a macrophage cell line (49); these studies focused on a
single enzymatic reaction that controls NFκB-activation: the
IKK-mediated degradation of NFκB-bound IκB. To investigate
the tissue scale control of NFκB and assist our intuitive
understanding, a new mathematical model was constructed. To
develop this simple quantitative tool we carefully considered the
enzymatic reactions that control NFκB activity. Conceptualizing
an abstracted model, we find that the amount of NFκB that is
capable of binding DNA in the nucleus is determined by the
abundance of the inhibitory IκB proteins, which in turn is a
function of the biochemical reactions governing IκB synthesis
and degradation (50). NFκB-bound IκBα is degraded through an
IKK-mediated pathway, but free IκBα, that is IκBα not bound
to NFκB, has a short half-life (51) determined by an IKK- and
ubiquitination-independent pathway (Figure 1A). Thus, in
principle, IKK-mediated NFκB activity (reaction K, Figure 1A)
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FIGURE 1 | A Simplified Model of NFκB Activity (SiMoN) can predict NFκB activity from 3 parameters. (A) Schematic of the key reactions controlling NFκB activity
through IκB metabolism. The amount of free, transcriptionally active, NFκB (NFκB activity) is tightly controlled by the amount of IκB; therefore IκB synthesis (reaction T)
and free IκB degradation (reaction P) may potentially offer alternative points of control. The primary, canonical activation pathway is through IKK (reaction K), however,
interferons do not directly activate IKK. (B) Schematic of the Simplified Model of NFκB (SiMoN), which analytically calculates NFκB as a result of parameters T,P and K.
(C) Modeled time-course concentrations of free NFκB (lower), in response to perturbed reaction rates obtained by multiplying the WT parameter value by the multiplier
indicated (upper) utilizing the simplified model. (D) Steady-state free NFκB concentrations in response to: increased IKK activity and IκB translation inhibition (left) and
increased IKK activity and free IκB degradation (right).
may be enhanced by reductions in IκB protein synthesis (reaction
T, Figure 1A) or in the free IκB half-life (reaction P, Figure 1A).
The schema of the Simplified Model of NFκB (SiMoN) is
given in Supplementary Figure 1 in Systems Biology Graphical
Notation (52) and consists of three ordinary differential
equations (ODEs) representing the rate of change of free (active)
NFκB, free IκB, and the NFκB-IκB complex. The concentration
of each constituent is a function of IκB synthesis, free IκB
degradation (an IKK-independent process) and degradation of
IκB from the IκB-NFκB complex (an IKK-dependent process)
(Figure 1B, parameters T, P, and K, respectively). SiMoN
approximates the average of multiple single cell simulations
of TLR NFκB responses (Supplementary Figure 2). Although
this model lacks the complexity of other NFκB signaling
models that describe the highly dynamic and variable NFκB
responses at single cell resolution (10), it provides for a
simplified, intuitive understanding of the reactions that may
be perturbed by signaling crosstalk and carry physiological
relevance within populations of cells. In addition to these
benefits of interpretation, SiMoN provides analytical benefits
over single-cell models. Indeed, by assuming that the network
reaches a steady-state quickly when reaction rates change (the
quasi-steady-state assumption), SiMoN can avoid the need for
simulation with numerical differential equation solvers. An
analytical solution for the quasi-steady-state concentration of
NFκB as a function of the kinase activity of IKK (K), free
IκB protein degradation (P), and IκB synthesis via translation
(T) was found (Figure 1B). NFκB activity can thus be directly
calculated when the values of these parameters are known, and
experimentally-measured changes in these parameters can be
directly interpreted.
We used SiMoN to examine how NFκB activity is a
function, not only of IKK activity, but also of translation
inhibition and IKK-independent free IκB degradation. Steady-
state concentrations of free NFκB were calculated to be increased
by either increasing active IKK, inhibiting IκB translation or
increasing free IκB degradation (Figure 1C). Dose response
analyses suggest that both inhibition of IκB synthesis and
free IκB degradation substantially amplify the response of free
NFκB to increasing IKK activity (Figure 1D). This means that
environmental conditions that do not activate IKK or alter its
activity may nevertheless potentiate or modulate NFκB activity.
To establish whether analytically investigating NFκB with SiMoN
could elucidate mechanisms of cross-regulation we turned to
the biologically important scenario of interferon modulation of
NFκB-driven inflammatory responses.
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Type I and II IFNs Enhance NFκB
Responsiveness to dsRNA
Exposure of naïve macrophages to Type I (IFNβ) or Type II
(IFNγ) interferons alters their physiological functions and gene
expression responses to pathogen-associated molecular patterns
(PAMPs) or inflammatory cytokines [reviewed by Glass and
Natoli (53); Ivashkiv and Donlin (54); Lawrence and Natoli (55)].
The underlying molecular mechanisms may involve changes
to state of the chromatin or epigenome (34), or alterations to
the signaling network state. We established two experimental
systems to examine whether and how interferon signaling
affected the control of NFκB signaling. To determine whether
NFκB activity is modulated by Type I Interferon, bone marrow-
derived macrophages (BMDMs) from either wild-type or type I
interferon receptor-deficient (ifnar−/−) mice were treated with
LPS (sensed by TLR4) or the dsRNA mimetic poly(I:C) (sensed
by TLR3, RIG-I, and MDA-5). Ifnar−/− macrophages do not
sense the tonic or PAMP-responsive production of IFNβ that
may be referred to as “IFNβ feedback” (56). Nuclear extracts
analyzed by electrophoretic mobility shift assay (EMSA) revealed
that in response to LPS NFκB induction was similar between
the WT and ifnar−/− BMDMs (Figure 2A, lower panel), but in
response to poly(I:C) it was similar only at the 1 h timepoint and
significantly reduced at later time points in the knockout (0.2
and 0.1 vs. 1.0 and 0.6 relative DNA binding activity, Figure 2A
upper panel).
As type II interferon is produced by T-cells and known
to polarize naive macrophages to a more activated state, we
addressed the role of type II interferon (IFNγ) on NFκB signaling
in primary peritoneal macrophages elicited by thioglycollate
(TEPMs). Cells were cultured with or without IFNγ for 24 h prior
to exposure to poly(I:C) or LPS before we examined the effect of
IFNγ priming on NFκB signaling by EMSA. Whereas, IFNγ did
not affect LPS-induced NFκB activation, it strongly enhanced the
NFκB responsiveness to poly(I:C) at 2 and 4 h (2.2 and 3.1 vs. 1
and 0.6 relative NFκB DNA binding activity, Figure 2B).
Recent single-cell imaging studies have revealed that NFκB
nuclear localization dynamics can show diverse single-cell
dynamics which can be obscured in bulk assays (49, 57, 58).
To quantitatively measure the effects of type I and type II IFN
pretreatment on NFκB dynamics BMDMs derived from a RelA-
mVenus reporter mouse were stimulated with poly(I:C) and
nuclear NFκB translocation was tracked in single cells. Plotting
the nuclear NFκB trajectory for 577 cells in each condition,
revealed that even in the context of cellular heterogeneity, either
interferon (Type I or II) increased nuclear NFκB activation at
late timepoints in response to poly(I:C) (Figure 2C). Indeed,
the average of these single-cells trajectories confirmed this also
(Figure 2D). Total NFκB abundance in response to poly(I:C)
did not increase with either IFNβ or IFNγ co-stimulation,
indicating increased nuclear NFκB was not due to increase
abundance of NFκB protein (Supplementary Figure 3). Given
that neither IFNβ nor IFNγ lead to IKK activation (as long as
the preparations are endotoxin-free), these results suggest that
late NFκB activity in WT macrophages responding to poly(I:C)
may be enhanced by conditioning macrophages with type I or
II interferon. We hypothesized that IFN-mediated regulation
of IκB synthesis and/or free IκB degradation might underlie
the observed cross-regulation, and we utilized SiMoN to dissect
the mechanism.
Type I IFN Feedback Amplifies
dsRNA-Induced NFκB Activity by Inhibiting
IκBα Synthesis
Type I interferon signaling is known to result in inhibition
of the translation of select mRNAs (59). To investigate
whether type I interferon feedback alters IκBα translation,
we measured IκBα protein synthesis in response to poly(I:C)
directly in WT and ifnar−/− BMDMs. Following stimulation
with poly(I:C) for 8 h, we pulsed with 35S-labeled Methionine,
and IκBαwas immunoprecipitated to examine newly synthesized
IκBα levels. Despite significantly lower concentrations of
IκBα mRNA template (9.7 vs. 3.3 fold induction, 1.2 ±0.6
log2 fold difference based on triplicates), the amounts of
35S-Met IκBα levels were similar in WT and ifnar−/−
BMDMs in response to poly(I:C) (Figure 3A, 3.7 vs. 3.2
fold induction, −0.1 ± 0.4 log2 fold change, based on
triplicates), indicating that an IFNAR-dependent process inhibits
translation during BMDM response to poly(I:C). Indeed,
quantitation of the fold induction of synthesis (35S-labeled
IκBα) over the fold induction of the mRNA level shows that
there is a 2-fold higher degree of IκBα translation in the
ifnar−/− BMDMs than wild-type counterparts (Figure 3A, 1.1
± 0.72 log2 fold change, based on summing the standard
deviations in the quadrature). While there is substantial
uncertainty in the quantitation of type I IFN-dependent
translation inhibition the above-described measurements place
the true value between 1 and 4-fold with 2-fold being the
geometric mean.
During the early phase of the poly(I:C) timecourse, prior
to any potential IFNβ feedback, NFκB activation is equivalent
in wild-type and ifnar−/− macrophages. However, at later
time points that may involve type I IFN feedback signaling,
NFκB activation is significantly lower in ifnar−/− BMDMs
(Figure 2A). To determine whether type I IFN-dependent
translation inhibition may account for the defects in NFκB
activation in ifnar−/− BMDMs, we used SiMoN to quantify
the effect of translational inhibition and IKK activity on NFκB
activation (Figure 3B). In both WT and ifnar−/− BMDMs,
TLR3/TRIF signaling triggers IKK and NFκB activity during
the early phase. By comparing NFκB activity using SiMoN with
and without the addition of a 2-fold increase IκBα translation
as identified experimentally in ifnar−/− BMDMs we found a
qualitative agreement in decreased late-phase NFκB activity
(Figure 3B). However, as the simplified model could only explain
a 3-fold difference in late-phase NFκB activity, rather than the
6-fold difference observed experimentally, as such our analysis
using SiMoN says that for NFκB to remain fully elevated in wild-
type cells in response to poly(I:C), translation inhibition alone is
not sufficient and an additional mechanism of cross regulation is
required. We wondered whether IFNβ may also modulate IKK
activity itself in response to poly(I:C)-induced NFκB activity.
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FIGURE 2 | Interferons potentiate NFκB activation in response to the viral PAMP poly(I:C). (A) Electrophoretic mobility shift assay (EMSA) of nuclear NFκB activity in
wild-type and ifnar−/− BMDMs stimulated with LPS and poly(I:C). Quantitated activity is indicated below each band. (B) EMSA of nuclear NFκB activity in TEPMs
cultured with or without IFNγ for 24 h prior to exposure to poly(I:C) or LPS. (A,B) show data representative of three biological replicates. Quantitations of
phosphorimager data are relative to peak activity in controls which is set to 1. (C) Single-cell tracking of RelA-mVenus localization in 577 Poly(I:C) stimulated BMDMs
cultured in the absence or presence (24 h) of IFNβ and IFNγ. Nuclear NFκB activity is indicated as nuclear:cytoplasmic ratio. The time-course response of each
tracked cell is displayed as a row in the heatmap with brighter colors corresponding with increasing nuclear localization of NFκB. (D) The average nuclear NFκB
activity of 577 tracked cells is shown for naïve and IFNβ- and IFNγ-primed conditions. (C,D) show data representative of two biological replicates.
The Type I IFN-Induction of RIG-I Enhances
dsRNA-Responsive IKK Activation
To test the model-generated prediction of an additional
molecular mechanism by which type I IFN regulates NFκB
activity in response to poly(I:C), IKK activity was examined. In
response to poly(I:C), the initial 1 h peak of IKK activity was
similar between WT and IFNAR-deficient BMDMs (4.1. vs. 3.7
fold i.e.,≤10% different), yet IKK activity was lower at 8 and 12 h
in ifnar−/− macrophages (2.1 vs. 1.5 fold at 8 h and 1.5 vs. 0.9
fold at 12 h, i.e.,≥30% different, Figure 4A). In contrast, the IKK
activity profiles in response to LPS between WT and ifnar−/−
BMDMs were similar (1.7 vs. 2.0 fold at 8 h and 1.9 vs. 1.9 fold
at 12 h).
Whereas, type I IFN feedback is important for inhibition
of IκBα synthesis, the IFN-dependent late-phase IKK activity
enhances IκBα degradation in response to poly(I:C). Both LPS
and poly(I:C) involve TRIF signaling to IKK and resultant
induction of IFNβ; however, the fact that we only observed
IFN feedback for potentiated NFκB activation in response to
poly(I:C) but not LPS led us to investigate whether a TLR3/TRIF-
independent mechanism for IKK activation may be boosted
by type I IFN signaling. To determine whether a TLR3/TRIF-
independent pathway contributes to late IFN-dependent IKK and
NFκB activity, BMDMs from wild-type and trif−/− mice were
treated with poly(I:C). As expected, we found that in the absence
of TRIF signaling, NFκB and IRF/ISGF3 activation by poly(I:C)
is severely diminished (Supplementary Figure 4A). However,
while the early NFκB activity at 1 h was completely lost, a small
amount of late 8–12 h NFκB activity was still observed in trif−/−
BMDMs, pointing to a TRIF-independent mechanism to activate
NFκB, one that may be boosted by type I interferon signaling.
We considered that the poly(I:C) added to the extra-
cellular medium may be taken up by macrophages to activate
intracellular cytoplasmic dsRNA receptors. The cytoplasmic
dsRNA receptors MDA5 (melanoma-differentiation-associated
gene 5) and RIG-I (retinoic-acid-inducible protein I) are known
to activate the IRF3 pathway, as well as the IKK complex
(60–62). We observed that RIG-I is inducibly expressed (> 5
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FIGURE 3 | Type I interferon signaling potentiates late NFκB activity by translational inhibition of IκBα (A) Experiments to determine IκBα translation rate in BMDMs.
Top, schematic of the experimental design: 35S-labeled Methionine pulsed at 0 h and following 8 h of Poly(I:C) stimulus. Middle, immunoprecipitates of IκBα following
a 35S-methionine pulse at either indicated timepoint. NFkB p65 immunoprecipitates are shown as normalization controls. Bottom, IκBα mRNA analysis using RNA
protection assay. Ribosomal protein gene L32 is provided as a control. These data are representative of three biological replicates. Quantitations are relative to basal
conditions which is set to 1. (B) Using SiMoN to determine whether the measured changes in the translation rate are sufficient to account for the NFkB activation
defect in ifnar−/− BMDMs. Left, timecourse simulation of NFκB activity in response to IKK activation following poly(I:C) stimulation with and without a 2-fold increase in
IκBα translation measured in ifnar−/− BMDMs (A). Right, bar graph of NFκB activity at the peak and 24 h time point as quantified from the simulation and experiment
(Figure 2A). This indicates that the increase in translation rate measured in (A) is not sufficient to account for the decrease in NFkB activity observed in Figure 2A.
fold) after 8 h of poly(I:C) or LPS treatment in an IFNAR-
dependent manner (Figure 4B). In trif−/− BMDMs, which are
deficient in autocrine IFNβ signaling, co-treatment with IFNβ
was required to up-regulate RIG-I expression (6.2 vs. 1.3 fold).
In addition, quantifying recent results from Cheng et al. (63)
revealed transcriptional upregulation of RIG-I mRNA (Ddx58)
in response to IFNβ conditioning (Supplementary Figure 4B).
Thus, we hypothesized that complementing trif−/− BMDMswith
exogenous IFNβ would enhance NFκB activation by poly(I:C).
Indeed, IFNβ co-stimulation of trif−/− BMDMs enhanced
induction of NFκB activity in response to poly(I:C) (8.8 vs.
3.2) but not LPS (Figure 4C). Furthermore, poly(I:C)-induced,
TRIF-independent IKK activity was enhanced by co-treatment
with IFNβ (Figure 4D). Together, these results suggest a model
in which type I interferon amplifies poly(I:C)-induced NFκB
activation through the expression of the intracellular dsRNA
sensor RIG-I or MDA5 (64), which activates the canonical NFκB
pathways through IKK.
To test whether poly(I:C) responsive NFκB activation is
enhanced by RIG-I in this manner, we examined if IKK and
NFκB activation in BMDMs is dependent on the RIG-I/MDA5
signaling adaptor IPS-1 (also known as mitochondrial anti-
viral signaling protein, MAVS), which signals to IKK and IRF3
(64). Similar to what we observed in the ifnar−/− BMDMs,
IKK activation by poly(I:C) in ips1−/− BMDMs is dampened
at late time points (Figure 4E), suggesting that late poly(I:C)
IKK activation is mediated by RIG-I/MDA5. Furthermore,
unlike our results from trif−/− BMDMs (Figure 4D), IKK
activation cannot be enhanced by co-treatment with IFNβ in
the ips1−/−macrophages (Figure 4E). Indeed, poly(I:C)-induced
NFκB activation in ips1−/− BMDMs was lower at 12 h than in
wild-type counterparts (Figure 4F) (0.4 vs. 0.9), though not as
low as observed in ifnar−/− BMDMs (Figure 2A) (0.2 vs. 1).
Our studies revealed two mechanisms by which type
I interferon signaling may modulate NFκB activation
(Supplementary Figure 4C). We first showed that interferon
signaling inhibits translation of IκBα mRNAs (Figure 3A); we
then, upon calculating with SiMoN that this alone was not
sufficient (Figure 3B), found that type I interferon induces
expression of the cytoplasmic receptor RIG-I which signals
to canonical IKK (Figure 4B). Inclusion of both translation
inhibition (quantified in Figure 3) and interferon-dependent
IKK activity (quantified in Figure 4A) into calculations of NFκB
activity with SiMoN fully explained the reduced late-phase
NFκB activity in ifnar−/− cells (Figure 4G), and delineates how
these two mechanisms combine to potentiate NFκB activation
by poly(I:C) (Figure 4H). Examining the two mechanisms
individually, we find that translational inhibition only partially
accounts for the increase in NFκB activation and that the
experimentally measured reduction in late-phase NFκB activity
in ifnar−/− can only be explained when the measured translation
inhibition is combined with a reduction in IKK activity
(Figure 4H).
Interestingly, both mechanisms of crosstalk between type I
interferon and NFκB signaling are specific for dsRNA, rather
than LPS-triggered NFκB activation, albeit for different reasons
(Supplementary Figure 4C). The RIG-I/MDA5-mediated cross-
regulation mechanism is specific because these receptors sense
dsRNA and not LPS. In contrast, the fact that the translational
inhibition mechanism shows specificity for dsRNA-triggered
NFκB activation may be explained by a kinetic argument:
translational inhibition has a diminished effect on NFκB
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FIGURE 4 | Type I interferon potentiates late NFκB activation by poly(I:C) by decreasing IκB translation and increasing bound IκB degradation via elevated RigI
expression. (A) Immunoprecipitation kinase assay (kinase A) of IKK activity in WT and ifnar−/− BMDMs in response to poly(I:C) and LPS. (B) Immunoblot of RIG-I
expression after 8 h of poly(I:C) or LPS treatment in WT, ifnar−/− and trif−/− BMDMs; and rescue of trif−/− cells with IFNβ. (C) EMSAs of NFκB activation by poly(I:C)
and LPS in trif−/− BMDMs with and without IFNβ co-treatment. (D) IKK activity in WT and ips−/− BMDMs exposed to poly(I:C) and in ips−/− cells with co-treatment
with IFNβ. (E) IKK activity in trif−/− BMDMs with and without IFNβ co-treatment. (F) EMSAs of NFκB activation by poly(I:C) in ips1+/+ and ips1−/− BMDMs. (A–D)
show a dataset representative of at least three biological replicates, and (E,F) show a representative of two biological replicates (we gratefully acknowledge Zhijian
James Chen for ips1−/− bone marrow). Quantitations are relative to basal or peak activity, which is set to 1. (G) (Left) Simulated NFκB timecourse in response to IKK
activation representative of poly(I:C) stimulation, with a 2-fold increase in IκBα translation (blue) or with both IκBα translation inhibition and 50% IKK activity reduction
as seen in ifnar−/− (green). (Right) Bar graph of NFκB activity at the peak and 24 h time point as quantified from simulations and experiments (Figure 2A). (H)
Heatmap of NFκB activity calculated using SiMoN for 50 increasing IKK activity values and 50 increasing degrees of translation inhibition (2,500 total points). In both
WT and ifnar−/− poly(I:C) stimulation results in increased IKK activity during the early phase. Following this WT cells undergo 50% translation inhibition and IKK activity
decreases. ifnar−/− cells lack translation inhibition (horizontal dashed line, Figure 3), and have decreased late-phase IKK activity [vertical dashed line, this (A–F)].
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activation when IKK-mediated IκB degradation is high. Thus,
high IKK activity induced by LPS is sufficient to produce
substantial NFκB activity and is only marginally enhanced by
interferon-mediated IκBα translational inhibition.
IFNγ Potentiates NFκB Activation by
Enhancing Free IκBα Degradation
Akin to type I interferon signaling in BMDMs, paracrine type
II interferon used for priming TEPMs enhances nuclear NFκB
DNA binding activity in response to poly(I:C) stimulation
more than 2-fold, whereas it had little effect on LPS-induced
NFκB activation (Figure 2B). To investigate the mechanism
by which IFNγ potentiates NFκB responsiveness to poly(I:C)
we again quantitatively examined the three tunable reactions
controlling IκBmetabolism using SiMoN (Figure 1). Specifically,
we wondered whether IκB translation is inhibited in a Type
II IFN-dependent manner in addition to the Type I-dependent
inhibition we identified. However, we found no evidence that
IFNγ treatment affects mRNA translation rates when translation
rates were measured using the 35S-Met pulse experiment
(Figure 5A). Next, we tested whether IFNγ alters the IKK
activity profile induced by poly(I:C) or LPS. To our surprise,
IFNγ pre-treatment did not alter LPS- or poly(I:C)-induced IKK
activity (Figure 5B).
As two out of the three reactions represented in SiMoN were
found unaffected by IFNγ we tested the third, the degradation
rate of unbound IκBα. Whereas, NFκB-bound IκBα is degraded
through IKK-mediated phosphorylation and the ubiquitin-
proteasome system, free IκBα is degraded independently of IKK
activity through a ubiquitin-independent, but 20S proteasome-
dependent mechanism (65, 66). To determine whether IFNγ
affects the stability of free IκBα, we employed MEFs deficient in
the NFκB proteins RelA, cRel, and p50 (termed “nfkb−/−”) in
which all IκBα is in fact free, a previously established assay system
for free IκBα turnover (51): nfkb−/− cells were treated with
IFNγ, and IκBα levels were measured by Western blotting. IFNγ
treatment of nfkb−/− cells resulted in a reduction of cellular IκBα
(Figure 5C). We next sought to confirm that IFNγ-mediated
reduction of free IκBα was due to enhanced degradation
rather than reduced synthesis. We found that addition of the
proteasome inhibitor MG132 after 24 h of IFNγ rescued the IκBα
level, whereas addition of MG132 to cells treated for 4 h with the
ribosomal inhibitor CHX did not (Figure 5D). Together, these
data suggest that IFNγ enhances the proteasomal degradation of
free IκBα.
We employed SiMoN to determine whether enhanced
degradation of free IκB protein may account for the
experimentally observed IFNγ-potentiated NFκB activity in
response to poly(I:C). Our Western blot analysis is consistent
with 10-fold higher degradation in IFNγ-primed cells; using
this number in simulations along with low and high IKK
activity curves representative of poly(I:C) and LPS, respectively,
resulted in more than 2-fold amplification of NFκB activation
in response to weak IKK activator poly(I:C) (Figure 5E).
SiMoN predicted that increased free IκBα degradation
affected the NFκB response speed, but did not substantially
change late (>1 h) NFκB activity to strong IKK activating
signals such as LPS but greatly increased the NFκB activity
to weak activating signals such as poly(I:C) (Figure 5E).
Strikingly, these predictions were validated by experimental
quantitation of NFκB fold induction, which demonstrated
similarly selective amplification of poly(I:C) but not LPS
(Figure 5F). To understand this selective amplification we used
SiMoN to quantify the relationship between IKK activity and
NFκB and how this dose-response relationship is altered by free
IκBα degradation. We observed a shift in the dose-response
relationship between NFκB and IKK activities with increasing
free IκBα degradation (Figure 5G). This shift selectively
amplifies the NFκB response to weaker IKK-activating stimuli
without substantially affecting strong IKK activators. Thus, the
specificity of IFNγ-mediated potentiation of NFκB activation for
poly(I:C), but not LPS, may be sufficiently explained by a kinetic
argument: namely, weak signals are subject to modulation by
crosstalk mechanisms, whereas strong signals are less sensitive
to such modulation.
The IFNγ-Induced PA28 Proteasome
Activators Accelerate Free IκBα
Degradation
As IFNγ-stimulated degradation of free IκBα may tune NFκB
responsiveness to poly(I:C) in tissue resident macrophages, we
considered the potential molecular mechanisms. SiMoN predicts
the molecular mechanism need not be poly(I:C) specific as
selective amplification of weak NFκB activators can emerge
through the kinetics of non-specific increased degradation of
free IκBα. Whereas, ubiquitinated proteins are recognized and
degraded by the 26S proteasome, which consists of the 20S barrel-
shaped core and a 19S regulatory cap, free IκBα was shown to be
degraded in a ubiquitin-independent manner (65). An alternative
11S regulatory cap, consisting of oligomers of the PA28α and
PA28β proteins allows for ubiquitin-independent entry into the
proteasome and has been implicated in antigen processing in
antigen-presenting cells (66, 67).
Western-blotting revealed that IFNγ treatment increased
PA28α and PA28β expression in both TEPMs (Figure 5H) and
MEFs (Figure 5I). Using nfkb−/− MEFs allowed us to assay
expression of free IκB protein, and examine whether PA28-
mediated proteasomal degradation controls free IκB abundance.
Knockdown of PA28α and PA28β by siRNA in nfkb−/− MEFs
resulted in increased IκBα levels in cells, particularly in cells
exposed to IFNγ (Figure 5I). Conversely, stable retroviral
overexpression of PA28α and PA28β in nfkb−/− MEFs led
to decreased levels of free IκBα (Figure 5J), demonstrating
that increased expression of PA28α and PA28β are sufficient
to increase degradation of free IκBα. Taken together, these
data suggest that the 11S proteasomal cap components PA28α
and PA28β are necessary and sufficient to increase free IκBα
degradation in IFNγ-primed cells.
To further demonstrate a direct role for the IFNγ-inducible
PA28 proteins in free IκBα degradation, purified IκBα was
subjected to an in vitro degradation assay with purified 20S
proteasome. The presence of PA28 proteins accelerated the
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FIGURE 5 | Type II interferon amplifies weak NFκB activating stimuli by enhancing free IκBα degradation. (A) IκBα translational synthesis rates in naïve and
IFNγ-conditioned TEPMs as revealed by 35S-Met pulse assay. Average and standard deviation of three biological replicates are shown. (B) Immunoblot for p-IκBα in
(Continued)
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FIGURE 5 | TEPMs exposed to either LPS or poly(I:C) with or without IFNγ priming. (C) Immunoblot of “free” IκBα compared to an actin control in MEFs deficient in
canonical NFκB proteins RelA, cRel and p50 (termed “nfkb−/−”) exposed to IFNγ. (D) Free IκBα levels in nfkb−/− MEFs compared to an actin control. Immunoblot of
lysates produced from MEFs exposed to 24 h priming with IFNγ or 4 h treatment with ribosomal inhibitor CHX, and followed by addition of proteasome inhibitor
MG132. (E) Predictions from the Simplified Model of NFκB (SiMoN) with low (10% at peak) IKK activity, representative of poly(I:C) (blue), and high (40% at peak) IKK
activity, representative of LPS. Values were calculated at 0, 0.5, 1, 2, and 4 h and fit with a smoothing spline for consistency with experimental time points. Free IκBα
degradation was modulated from the default value (dashed lines) to 10-fold higher (solid lines) based on quantification of immunoblot in 5B. (F) Time course of NFκB
induction (quantitated from EMSAs) in naïve or IFNγ-conditioned TEPMs stimulated with poly(I:C) and LPS. (G) Nuclear NFκB activity calculated using SiMoN as a
function of bound IκBα degradation (IKK-activity, x-axis) and free IκBα degradation (colored lines). The blue and red arrows indicates the free IκBα
degradation-dependent increase in NFκB activity for low and high IKK activities indicative of poly(I:C) and LPS, respectively. (H) Immunoblots of proteasome activator
28 (PA28) levels in TEPMs following exposure to IFNγ. (I) Immunoblots for IκBα and proteasome activator 28 (PA28) in nfkb−/− MEFs. Both conditions were repeated
following PA28 siRNA-mediated knockdown. (J) Immunoblot of IκBα and PA28 levels in nfkb−/− MEFs transduced with retroviral transgenes. (K) Coomassie-stained
SDS-PAGE showing free IκBα and PA28α/β levels following incubation with increasing amounts of purified 20S proteasome (upper panel) contrasted with
GST-ubiquitin levels (lower panel), which serves as a negative control. (B–D) show a dataset representative of at least three biological replicates (H–K) show a dataset
representative of two biological replicates. Quantitations are relative to basal or t = 0 activity, which is set to 1.
degradation of IκBα in this cell-free system (Figure 5K, upper),
and this finding was specific to IκBα as the use of ubiquitin as the
substrate in the same assay showed no change upon addition of
PA28 proteins (Figure 5K, lower).
IFNγ-Mediated Degradation of Free IκBα
Sensitizes NFκB to Weak Activating Signals
Our studies revealed that type II interferon signaling amplifies
NFκB activation through increasing free IκBα degradation
(Supplementary Figure 5A). SiMoN predicts that the amplifying
effect of increasing free IκBα degradation is not specific
to poly(I:C), but general to other weak NFκB inducing
signals (Figure 5G). To further validate this prediction we
utilized UV radiation, a known weak activator of NFκB,
causing translation inhibition that allows for depletion of
IκBα through its constitutive turnover (68). Consistent with
the model predictions, pretreatment with IFNγ increased
the NFκB response to UV in wild-type immortalized MEFs
(Supplementary Figure 5B).
SiMoN was used to simulate the unfolded protein response
(UPR) (69) which increases free IκBα degradation rates
(simulating the presence of IFNγ). Whereas, increasing
the free IκBα degradation rate had little effect on the
response to large IKK activity changes such as for LPS
(Figure 5G), it is predicted to result in a significant
increase in the peak of NFκB activity in response to
UPR (Supplementary Figure 5C).
To test this prediction and establish whether increased
expression of PA28α and PA28β is sufficient to alter NFκB
responsiveness to UPR, wild-type MEFs were retrovirally
transduced with PA28α and PA28β. Overexpression of
PA28α and PA28β increased the NFκB response to UPR
induced by thapsigargin (Supplementary Figure 5D).
The NFκB response to the strong IKK activator, TNF,
however, was unaffected by the overexpression of
PA28α and PA28β, consistent with the computational
prediction that stronger inducers of IKK activity are not
sensitive to increased free IκBα degradation (Figure 5G
and Supplementary Figure 5D). In addition, pa28-
deficient MEFs showed reduced response to thapsigargin
(Supplementary Figure 5E). In addition, quantifying recent
results from Cheng et al. (63) revealed transcriptional
upregulation of PA28α/β (Psme1/2) in response to IFNγ
conditioning (Supplementary Figure 5F). Together, these
data support a model in which IFNγ enhances NFκB
responses to weak stimuli by increasing the IKK-independent
degradation of free IκBα via enhancement of the 11S proteasomal
degradation pathway.
DISCUSSION
Here we presented a new simplified mathematical model
of NFκB activity (SiMoN) and applied it to studying how
interferons modulate NFκB activity. Although this model lacks
the some of the molecular network detail of other NFκB
signaling models that describe the highly dynamic and variable
NFκB responses at single cell resolution (10), it provides
for an intuitive understanding of how NFκB is controlled
at the tissue scale. Specifically, the abstraction revealed that
NFκB activity is governed fundamentally by three reactions
that may be modulated by signaling crosstalk. This is an
important modification of the prevailing research focus on
just one of these: the IKK-controlled degradation of NFκB-
bound IκB. Our work demonstrates that a focus on IKK
alone has substantially limited previous studies into mechanisms
of signaling crosstalk by cytokines that themselves do not
activate NFκB. in this manner it is important to point out that
other mechanisms that do not affect IκB metabolism may also
control NFκB activity (e.g., the nuclear import/export machinery,
post-translational modifications of NFκB, and expression of
NFκB protein family members) and could be included in
further studies.
In response to infection, innate immune responses must
be delicately coordinated to ensure that it is sufficient to
mount an effective defense, but not excessive so as to avoid
the potentially harmful effects of inflammation. A central
regulator of this response is NFκB, which can be activated
by a variety of pathogen sensors, such as RIG-I/TLR3 and
TLR4 in response to viral RNA and bacterial LPS, respectively.
Infections also trigger an upregulation of type I interferon
expression and expression of type II IFNγ by T and NK cells,
thus providing a variety of cytokine milieus that potentially
affect the NFκB-driven immune response. We have shown here
how both type I and type II interferons engage in signaling
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crosstalk with the core of IκB metabolism, effecting a stimulus-
specific potentiation of NFκB activation, yet do so via different
molecular mechanisms.
Through quantitative analysis of experimental data using
SiMoN we identified two reactions in the core NFκB signaling
module that are modulated by type I interferon feedback.
Reduction in IκBα translation inhibition combined with
modulation of IKK activity through RIG-I/MDA5 and IPS-
1 results in increased late stage NFκB activation in response
to poly(I:C) (Figure 6A). Type II interferon priming was
found to modulate a third reaction, that we had not
tested in response to type I interferon. Namely, type II
interferon increased free IκBα degradation via the induction
of immunoproteasomal cap proteins, thereby amplifying NFκB
activation in response to weakly activating stimuli such as
poly(I:C) (Figure 6A). IFNγ exposure also amplified the NFκB in
response to ribotoxic stimuli, such as UPR, which induces NFκB
signaling without inducing IKK (Supplementary Figure 5C), but
showed less effect on LPS which activates NFκB by strongly
inducing IKK.
Interestingly, the selective amplification of low IKK activating
signals by IFNγ can be intuitively seen by studying the analytical
solution to SiMoN. By first investigating a scenario without free
IκB degradation such that the term P tends toward 0 we obtain:
lim
p→0
0.1kfK+
√(
0.1kfK− PK
)2
+ 0.4PK
(
Tkf + Kkf
)
− PK
2kf (T+ K)
=
0.1kfK+ 0.1kfK
2kf (T+ K)
=
0.1K
(T+ K)
For a weak IKK activating stimulus (K = 6% · kikk) SiMoN
gives ∼0.028µM of NFκB activity and for strong IKK activators
(K = 60% · kikk) SiMoN gives ∼0.078µM of NFκB activity
(T = 0.055 min−1 throughout). In contrast if we investigate the
effect of enhancing free IκB degradation such that P is high we
see that the limit does not depend on IKK activity:
lim
p→∞
0.1kfK+
√(
0.1kfK− PK
)2
+ 0.4PK
(
Tkf + Kkf
)
− PK
2kf (T+ K)
= 0.1 µM
Therefore, the analytical solution reveals that free IκBα
degradation can amplify NFκB activity in response to weak IKK
activating over 3.5-fold (0.028 to 0.1µM), but for strong IKK
activating stimuli the amplification is far less substantial, with
only around a 28% increase (from 0.078 to 0.1 µM).
Whether a stimulus is weak or strong depends on both
dose and the pathways dose response. As LPS activation
of NFκB is largely governed by the ultra-sensitive MyD88
pathway (49), LPS typically activates IKK strongly (or not
at all). PolyIC on the other hand relies on the TRIF
pathway, which, in macrophages, activates IKK more weakly.
Thus, the crosstalk mechanisms identified here allow type
I and type II interferons to potentiate NFκB activity in
cells exposed to viral RNA, and less so when exposed
bacterial LPS. Given the importance of coordinating innate
immune defenses of localized macrophages, and system-wide
adaptive immune responses during to viral infection, we
suggest that the molecular mechanisms of interferon-NFκB
crosstalk described here have pathophysiological relevance
particularly where interferon signaling and inflammation are
linked such as chronic inflammatory diseases and cancer
(70, 71). By rigorously quantifying NFκB activation and IFN
in physiological conditions, SiMoN may be used to explain
seemingly conflicting physiological observations. For example,
while greater inflammation is seen in leishmaniasis when the
host IFN response is induced by parasites harboring Leishmania
RNA virus (LRV) (28, 29) others have found TLR4 mediated
NFκB activation to be unaffected by IFNγ (34). The selective
IFN-dependent amplification of NFκB activity discovered here
may reveal why some inflammatory conditions are susceptible
to IFN-mediated crosstalk while others are not. Further work
is required to quantify the degree of NFκB activation in diverse
physiological conditions.
Further work is required to quantify the impact of selective
amplification of NFκB activity on NFκB-target gene expression.
A number of factors make such a task difficult, including
gene-specific combinatorial control of NFκB-target genes
in combination with other transcription factors interferon-
regulatory factors [IRFs and STATs, Cheng et al. (72)].
Recent work has also identified highly gene-specific effects
of interferons on chromatin accessibility and as such even
genes lacking interferon responsive elements (IREs) may be
subject to complex crosstalk (63). Similar signaling crosstalk
may affect transcriptional elongation, mRNA processing
and turnover. Disentangling these effects will require
careful quantitative consideration, perhaps with the aid of
a quantitative model of the mechanism controlling mature
mRNA abundance.
The simplified model presented here enabled an analytical
solution for the quasi-steady-state concentration of NFκB
as a function of bound IKK activity, free IκB degradation,
and IκB translation affinity (Figures 1B, 6B). NFκB activity
can thus be calculated when the values of these parameters
are known, without the need for timecourse simulations.
This has enabled us to make SiMoN available through a
web interface (signalingsystems.ucla.edu/tools/SiMoN.html) to
allow others to interpret the impact of perturbations in
these core processes on NFκB activity. Indeed, NFκB activity
may be visualized in a four-dimensional plot (color cube)
as a function of the three reactions (Figure 6C). Slices
of the color cube in any of the three dimensions reveal
NFκB activity as a function of two of the reactions at
specific values of the third reaction. Thus, within a single
image NFκB activity can be related to the activity of
three interferon-tunable reactions that control IκB synthesis
and degradation.
MATERIALS AND METHODS
Mathematical Modeling
A new mathematical model was constructed that consists
of three ordinary differential equations (ODEs) to describe
NFκB activation in response to TLRs and enable studies
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FIGURE 6 | The mechanisms underlying interferon signaling crosstalk on NFκB. (A) Type I interferons reduce IκB expression and increase IKK activity through RIG-I
and IPS-1. Type II interferons increase free IκB degradation through a PA28-dependent process. (B) Type I interferons reduce translation of IκBα and increase the
expression of the cytosolic viral sensor to allow for enhanced IKK mediated degradation of NFκB-bound IκBα. Type II interferon increases the degradation rate of free
IκBα. All mechanisms potentiate the NFκB response to weak signals emanating from viral PAMP sensors, but have little effect on bacterial-MyD88-mediated
responses. (C) Three-dimensional heatmap of nuclear NFκB concentrations as a function of three biochemical reactions: IKK activity (reaction K), IκB translation
efficiency (reaction T) and free IκB degradation (reaction P). The point in this parameter space reached following Poly(I:C) and LPS stimulus is marked with black
circles. Signaling crosstalk by Type I and Type II interferons produce distinct trajectories through this three-dimensional parameter space (marked with white arrows to
white circles).
of signaling crosstalk in cell populations. NFκB activity is
a function of its interaction with IκB, whose abundance is
controlled via NFκB-dependent synthesis and two degradation
reactions (51).
dNFκB
dt
= −kf · [NFκB] · [IκB]
+ kikk · ikkActivity · [NFκB− IκB] (1)
dIκB
dt
= −kf · [NFκB] · [IκB]+ kIκBExp · [NFκB]
− kIκBDeg · [IκB] (2)
dNFκB− IκB
dt
= +kf · [NFκB] · [IκB]
− kikk · [NFκB− IκB] (3)
All parameters were derived from the existing cellular model of
NFκB regulation (12) as follows:
Frontiers in Immunology | www.frontiersin.org 12 June 2019 | Volume 10 | Article 1425
Mitchell et al. Dissecting Interferon Cross-Regulation of NFκB
Model construction and analysis was performed in
COPASI:Biochemical System Simulator (73). When compared
to the model of Werner et al. (12) from which it was derived,
SiMoN reduces complexity by assuming all reactions are in
a single cellular compartment with all unbound (12) NFκB
assumed to be transcriptionally active. Indeed, the majority of
inhibited NFκB is found in the cytoplasm with free NFκB quickly
translocating to the nucleus in both experimental and model
systems (10). In addition, only the predominant NFκB-inhibitor
(IκBα) is considered, and IκBε and IκBβ, which are bind a
relatively minor portion of NFκB are ignored (74). To further
simplify the model, the two reactions of NFκB-dependent IκBα
mRNA expression and subsequent protein synthesis are reduced
to a single NFκB-dependent IκBα protein production reaction in
SiMoN, similar to other reduced models (15–18).
For the exploratory analysis in Figure 1, a steady-state phase
was run with default parameters and then initial conditions
were updated to the final concentrations from the steady-state
phase. The indicated parameters were then scanned using the
“Parameter Scan” task in COPASI with a 3-h time course.
kIκBExp was scanned from 0.5 to 1x the default parameter
value with samples every 0.1 (Figure 1A), kIκBDeg was scanned
from 1 to 5x the default parameter value with samples every 1
(Figure 1B) and the ikkActivitymultiplier was scanned from 1 to
2x the default parameters with samples every 0.25 (Figure 1C).
Two dimensional parameter scans were performed using nested
parameter scan tasks in COPASI to repeatedly perform a
steady-state analysis at each parameter value as indicated
(Figure 1D). In order to quantify the effect of IκBα translation
on Poly(I:C) responses (Figure 3B) the model was modified
to add an additional modifier to the rate of IκBα expression
(IκBα expression = kIκBExp · tslModifier, tslModifier = 1). A
Copasi event was added to trigger at 200min updating the
translation rate modifier parameter, and a parameter scan task
in Copasi was used to scan this modifier at 1 (no change) and 2
(double IκBα expression). IKK activity dynamics were simulated
by modulating the multiplier of NFκB-bound IκB degradation
reaction (parameter ikkActivity). Input curves for and poly(I:C)-
induced IKK activity (Figure 3A) were quantified using ImageJ
software (75). A piecewise function, which interpolated between
the time points in the figure, was created to represent IKK
activity through modulating the multiplier of NFκB-bound IκB
degradation reaction (parameter ikkActivity).
In order to simulate the modulation of IKK activity ifnar−/−
(Figure 4G) two additional multipliers were added scaling early
IKK activity (0–200min) and late IKK activity (>200min) and
these were set to 0.9 and 0.6, respectively to represent the fold
change in IKK activity measured in ifnar−/− BMDMs by IKK
kinase assay (Figure 4A). Simulations of the effect of free IκBα
degradation on Poly(I:C) and LPS responses (Figures 5E,F) were
obtained by multiplying the ikkActivity by 0.5 for Poly(I:C) and
2 for LPS to give peak IKK activity at ∼7% for Poly(I:C) and
∼30% for LPS, and a parameters scan task was use to adjust
kIκBDeg to 12 min
−1 for both input curves. Simulations of the
unfolded protein response (Supplementary Figure 5C) involved
applying, at time t = 0, a 50% reduction on the IκB translation
rate, while keeping the NFκB-bound IκB degradation reaction
rate (dependent on IKK activity) constant at its basal level. In
the analytical analysis and figures parameters are abbreviated:
ikkActivity · kikk = K, kIκBDeg = P, kIκBExp = T.
Mouse Strains and Cell Culture
Bone Marrow-Derived Macrophages (BMDMs) were generated
from C57BL/6, trif−/−, ips1−/−, and ifnar−/− mice with
L929 cell–conditioned medium for 8 days. Thioglycollate
Elicited Peritoneal Macrophages (TEPMs) were isolated from
the peritoneal cavity 4 days after injection of thioglycollate.
Mouse Embryonic Fibroblasts (MEFs) of indicated genotype
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(wild-type or nfkb1−/−crel−/−rela−/−) were prepared from
embryonic day 12 to 14 embryos and were cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM) containing
10% bovine calf serum for up to six passages. Cells were
stimulated with LPS (0.1µg/ml; Sigma, B5:055), poly(I:C)
(50 µg/ml: Amersham Biosciences), IFNβ (250 U/ml: PBL
Biomedical Laboratories), IFNγ (eBioscience: 10 U/ml), or
thapsigargin (Sigma-Aldrich). For siRNA, the target sequences
for PA28α and PA28β were AAGCCAAGGTGGATGTGTT and
AGCGAGCAAGGCCAGAAGC, respectively. Oligonucleotides
were transfected into nfkb1−/−crel−/−rela−/− MEFs with
lipofectamine. This study was carried out in accordance with
the principles of the Basel Declaration and recommendations
of Association for Assessment and Accreditation of Laboratory
Animal Care International (AAALAC) which accredits UCLA’s
animal care program. UCLA’s AnimalWelfare Assurance number
with the Department of Health and Human Services Office
of Laboratory Animal Welfare is A3196-01. The protocol
was approved by the UCLA Institutional Animal Care and
Use Committee, known as the Chancellor’s Animal Research
Committee (ARC).
Live Cell Imaging of NFκB Localization
BMDMs derived from a RelA-mVenus reporter mouse (to
be described) were plated on eight-well µ-slides (ibidi) and
stimulated with poly(I:C) without or with IFNβ or IFNγ.
Conditions were maintained at 5% CO2 and 37
◦c throughout
imaging with a Zeiss AxioObserver using a 40x oil immersion
objective, LED (light-emitting diode) fluorescence excitation, and
CoolSnap HQ2 camera. RelA-YFP and H2B-mCherry images
were collected every 5min over 12 h and exported into MATLAB
where analysis was performed as previously described (76).
Biochemical Assays With Cell Extracts
Nuclear extracts from BMDMs were prepared by
high salt extraction. Western blotting analysis and
Electrophoretic Mobility Shift Assays (EMSAs) were
conducted with standard methods as described
previously (12, 46, 68). The κB EMSA probe was:
GCTACAAGGGACTTTCCGCTGGGGACTTTCCAGGGAGG.
For Western blotting analysis and supershift assays we used
antibodies against p65 (Santa Cruz Biotechnology, sc-372), p50
(sc-114), α-tubulin (sc-5286), p50 (N. Rice, NC-1263), lamin A/C
(Cell Signaling, #2032), PA28α/β (Cell Signaling, #2408/2409),
and IRF3 (Cell Signaling, #4962); Guinea pig anti-RIG-I was used
as described previously (77). IKK activity assays were previously
described (68). In vivo pulse labeling of BMDMs was done with
100 µCi/ml trans 35S-Met label (MP Biomedicals, Inc.) using the
indicated time courses. IκBα was immunoprecipitated (sc-371)
and proteins were resolved on 8% SDS-PAGE, visualized by
autoradiography, and quantified with Imagequant software.
Ribosomal inhibitor cyclohexamide (CHX) and proteasomal
inhibitor MG132 were used to block protein synthesis and
degradation, respectively, and as described previously (69). Gene
expression studies employed quantitative RNAse protection
or qPCR assays, as described (78, 79). Quantitative data of
biological replicates was analyzed with indicated statistical tests
and visualized in R, Prism, or Excel software.
Proteasomal in vitro Degradation Assay
As previously described (80), 20S proteasome particles were
purified from bovine blood using four chromatographic steps
(Q-sepharose, Sephacryl S-300, Phenyl sepharose and Mono-
Q). PA28α and β subunits were expressed in E. coli and
purified separately followed by hetero complex formation by
refolding following the method described by Song et al. (81).
PA28αβ was mixed in 4-fold molar excess with 20S at 25◦C,
and the resulting proteasome complex was incubated with
recombinant IκBα immediately following its elution from a
Superdex 200 column. Recombinant IκBα was mixed in varying
molar ratios with purified proteasome in a reaction buffer
containing 200mM NaCl, 20mM Tris HCl, pH 7.1, 10mM
MgCl2, and 1mM DTT and incubated at 25◦C. The reaction
was quenched by the addition of 4X SDS dye and boiling for
1min at 95◦C. The products were then separated by SDS-
PAGE and visualized by Coomassie staining. To ensure the
specificity of the degradative activity of the proteasome the
degradation assay was also performed using stably folded GST
tagged di-ubiquitin (GST-diUb).
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